Drug-Resistant Epilepsy: Treatment Options Beyond Medication

Around 1 in 3 people with epilepsy keep having seizures despite trying multiple medications. Epilepsy is classified as drug-resistant when two appropriate antiseizure medications at the right doses haven’t stopped the seizures, and at that point, surgery, devices, and dietary therapies become the real conversation.

According to Dr. Guruprasad Hosurkar, a leading neurologist in Bangalore,
“When two medications haven’t worked, the odds of a third or fourth drug achieving full seizure control drop below 5%. That’s when I tell families the real evaluation hasn’t even started yet. We need to find out exactly where in the brain seizures are coming from, because that answer opens up treatment options that medications simply can’t replicate.”

Drug-resistant epilepsy isn’t a permanent verdict, but it does mean the medication route has reached its ceiling. Understanding what actually defines it, and what needs to be ruled out first, changes everything about where treatment goes next.

• Failed drug threshold: 2 or more medications: Epilepsy is drug-resistant when seizures persist after two appropriate antiseizure drugs at adequate doses, with each new drug after that carrying less than a 5% chance of success.
• Wrong diagnosis is more common than expected: Some patients carrying a drug-resistant label are actually having non-epileptic events, cardiac syncope, or TIAs, and ruling these out comes before any surgical evaluation.
• Drug-seizure type mismatch matters: Prescribing the wrong drug for the wrong seizure type creates apparent resistance that has nothing to do with brain structure and everything to do with the prescription.
• Onset zone mapping is non-negotiable: High-resolution MRI, prolonged video-EEG, and sometimes PET or SPECT imaging identify exactly where seizures start, and that single answer determines which treatments are on the table. Families with years of failed adjustments benefit from understanding epilepsy in adults and why this step carries so much weight.

Getting these four things right before moving forward is what separates a productive next step from repeating the same cycle with a different drug name.

Once medication has genuinely reached its limit, drug-resistant epilepsy has a real set of evidence-based alternatives. The right option depends on whether seizures come from one identifiable brain region or several, and whether that region can safely be targeted.

• Resective surgery: 60 to 70% seizure-freedom rate: For temporal lobe epilepsy with visible hippocampal sclerosis on MRI, removing the seizure-generating tissue gives the strongest long-term outcomes no medication trial can match.
• Neurostimulation devices: 50% or more seizure reduction: VNS, RNS, and thalamic Deep Brain Stimulation surgery are valid options when seizures start in multiple regions or areas too critical to remove surgically.
• Laser thermal therapy (LITT): minimally invasive alternative: A laser probe guided by real-time MRI destroys the seizure focus without open surgery, with shorter stays and faster recovery for deep or hard-to-reach lesions.
• Ketogenic diet: medically supervised, not a wellness trend: A high-fat, very low-carbohydrate diet achieves greater than 50% seizure reduction in roughly half of drug-resistant cases and is first-line treatment for specific metabolic epilepsies.

Each of these options has a defined patient profile it suits best, which is why the evaluation step always comes before the treatment decision, not after.

Dr. Guruprasad Hosurkar leads the Movement Disorders and Parkinson’s Disease Programme at KIMS Hospital, Mahadevapura, where he established India’s first Adaptive Closed-Loop DBS centre. His expertise in neuromodulation covers the full range of device-based therapies used in drug-resistant epilepsy, including VNS, RNS, and thalamic DBS, alongside the pre-surgical evaluation work-up that determines which patients are genuine candidates. Patients get a direct, honest assessment of what each option can realistically deliver.

References

1. 1. 1. Kalilani L, et al. The epidemiology of drug-resistant epilepsy: a systematic review and meta-analysis
      2. Tang F, Hartz AMS, Bauer B. Drug-Resistant Epilepsy: Multiple Hypotheses, Few Answers